Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 3, 2014, Pages 465-471

  Galsky, Matthew D ^a   Posner, Marshall ^a   Holcombe, Randall F ^a   Lee, Karen M ^a   Misiukiewicz, Krzysztof ^a   Tsao, Che Kai ^a   Godbold, James ^a   Soto, Rothschild ^a   Gimpel Tetra, Kiev ^a   Lowe, Nancy ^a   Oh, William K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder cancer; Carboplatin; Cisplatin; Dovitinib; Fibroblast growth factor receptor; Gemcitabine

Indexed keywords

CARBOPLATIN; CISPLATIN; DOVITINIB; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CARBOPLATIN; CISPLATIN; COLONIC NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; QUINOLONES; THROMBOEMBOLISM; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84907347811     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2518-5     Document Type: Article

References (31)

1. Folkman J (2006) Angiogenesis. Annu Rev Med 57:1-18. doi:10.1146/annurev. med.57.121304.131306
2. Chung AS, Lee J, Ferrara N (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10:505-514. doi:10.1038/nrc2868
3. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974. doi:10.1038/nature04483 (Pubitemid 43093963)
4. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795-803. doi:10.1038/nrc909
5. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2):116-129
6. Kerbel RS (2005) Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 8(4):269-271
7. Brooks N, Kilgour E, Smith PD (2012) Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 18:1855-1862. doi:10.1158/1078-0432.CCR-11-0699
8. Greenman C, Stephens P, Smith R et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446(7132):153-158 (Pubitemid 46398669)
9. Knowles MA (2008) Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Futur Oncol 4(1):71-83 (Pubitemid 351372608)
10. Iyer G, Al-Ahmadie H, Schultz N et al (2013) Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 31(25):3133-3140. doi:10.1200/JCO.2012.46.5740
11. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5(11):e13821. doi:10.1371/journal.pone.0013821
12. Quintela-Fandino M, Colomer R (2013) Dovitinib lactate: multikinase inhibitor antiangiogenic agent oncolytic. Drugs Future 38:81-89
13. Angevin E, Lopez-Martin JA, Lin C-C et al (2013) Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 19:1257-1268. doi:10.1158/1078-0432.CCR-12-2885
14. Andre F, Bachelot TD, Campone M et al (2011) A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. J Clin Oncol 29:8-10
15. Azab AK, Azab F, Quang P et al (2011) FGFR3 is overexpressed Waldenstrom macroglobulinemia and its inhibition by dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res 17:4389-4399. doi:10.1158/1078-0432.CCR-10-2772
16. Sivanand S, Pena-Llopis S, Zhao H et al (2012) A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med 4:137ra75-137ra75. doi:10.1126/scitranslmed.3003643
17. Motzer RJ, Porta C, Bjarnason GA et al (2012) Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies. ASCO Meet Abst 30:TPS4683. doi:10.1111/j.1464-410X.2012.11171.x
18. Tai W-T, Cheng A-L, Shiau C-W et al (2012) Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol Cancer Ther 11:452-463. doi:10.1158/1535-7163.MCT-11-0412
19. Sarker D, Molife R, Evans TR et al (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14(7):2075-2081. doi:10.1158/1078-0432.CCR-07-1466 (Pubitemid 351551118)
20. Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM (2011) Phase I/II and pharmacodynamic study of dovitinib (TKI258) - an inhibitor of fibroblast growth factor receptors and VEGF receptors-in patients with advanced melanoma. Clin Cancer Res. doi:10.1158/1078-0432.ccr-11-1747
21. Motzer RJ, Porta C, Vogelzang NJ et al (2014) Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. doi:10.1016/S1470-2045(14)70030-0
22. Galsky MD, Hahn NM, Powles T et al (2012) Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 11(2):175-181. doi:10.1016/j.clgc.2012.10.001
23. Funakoshi T, Latif A, Galsky MD (2014) Safety and efficacy of addition of VEGFR or EGFR-family small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials. Cancer Treat Rev 40(5):636-647
24. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28(13):2280-2285. doi:10.1200/JCO.2009.27.2757
25. Sonpavde G, Je Y, Schutz F et al (2013) Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 87(1):80-89. doi:10.1016/j.critrevonc.2012.12.006
26. Seng S, Liu Z, Chiu SK et al (2012) Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis. J Clin Oncol 30(35):4416-4426. doi:10.1200/JCO.2012.42.4358
27. Proverbs-Singh T, Chiu SK, Liu Z et al (2012) Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst 104(23):1837-1840. doi:10.1093/jnci/djs435
28. Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. doi:10.1038/ nature12965
29. Milowsky MI, Dittrich C, Duran Martinez I et al (2013) Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. ASCO Meet Abstr 31(6 Suppl.):255
30. Herrera-Abreu MT, Pearson A, Campbell J et al (2013) Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov 3(9):1058-1071. doi:10.1158/2159-8290.CD-12- 0569
31. Sequist LV, Cassier P, Varga A et al (2014) Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. In: American Association for Cancer Research 2014 annual meeting, p CT326